JD Supra December 29, 2021
Bass, Berry & Sims PLC

On December 23, 2021, the United States Food and Drug Administration (FDA) announced the availability of a draft guidance for industry, investigators, and other stakeholders entitled “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations” (Guidance). The Guidance synthesizes the FDA’s recommendations, based on input solicited from numerous stakeholders over the course of the last six years. Once finalized, the Guidance will directly affect drug, device, and biotech companies, as well as research institutions, that sponsor FDA-regulated clinical investigations incorporating digital health technologies (when used for healthcare related purposes, “DHTs” as defined in the Guidance). It will also affect investigators, research sites, and institutional review boards (IRBs) that conduct or review those clinical investigations. FDA is accepting comments on...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, FDA, Govt Agencies, Pharma, Pharma / Biotech, Technology
March Fundraising Roundup: 7 Provider Tech Startups That Closed Rounds This Month
Pelago Defies Digital Health Funding Drought, Raises $58M
Digital health venture capital deals stagnate
Finger on the Pulse: The State of Primary Care in the U.S. and Nine Other Countries
Embracing digital transformation with a digital factory

Share This Article